tbuckley/cabot-search huggingface dataset:
Reflecting on a Year at the Helm of <i>Diabetes Care</i>
Authors: Steven E. Kahn, Cheryl A.M. Anderson, John B. Buse, Elizabeth Selvin, Sonia Y. Angell, Vanita R. Aroda, Alice Y.Y. Cheng, Thomas Danne, Justin B. Echouffo-Tcheugui, Stephanie L. Fitzpatrick, Meghana D. Gadgil, Amalia Gastaldelli, Anna L. Gloyn, Jennifer B. Green, Ania M. Jastreboff, Alka M. Kanaya, Namratha R. Kandula, Csaba P. Kovesdy, Neda Laiteerapong, Kristen J. Nadeau, Jeremy Pettus, Rodica Pop-Busui, Jennifer E. Posey, Camille E. Powe, Casey M. Rebholz, Michael R. Rickels, Naveed Sattar, Jonathan E. Shaw, Emily K. Sims, Kristina M. Utzschneider, Adrian Vella, Cuilin Zhang
Journal: Diabetes Care (2023)
Mechanisms and therapeutic strategies of extracellular vesicles in cardiovascular diseases
Authors: Qirong Li, Qiang Feng, Hengzong Zhou, Chao Lin, Xiaoming Sun, Chaoyang Ma, Liqun Sun, Gongliang Guo, Dongxu Wang
Journal: MedComm (2023)

Abstract Cardiovascular disease (CVD) significantly impacts global society since it is the leading cause of death and disability worldwide, and extracellular vesicle (EV)‐based therapies have been extensively investigated. EV delivery is involved in mediating the progression of CVDs and has great potential to be biomarker and therapeutic molecular carrier. Besides, EVs from stem cells and cardiac cells can effectively protect the heart from various pathologic conditions, and then serve as an alternative treatment for CVDs. Moreover, the research of using EVs as delivery carriers of therapeutic molecules, membrane engineering modification of EVs, or combining EVs with biomaterials further improves the application potential of EVs in clinical treatment. However, currently there are only a few articles summarizing the application of EVs in CVDs. This review provides an overview of the role of EVs in the pathogenesis and diagnosis of CVDs. It also focuses on how EVs promote the repair of myocardial injury and therapeutic methods of CVDs. In conclusion, it is of great significance to review the research on the application of EVs in the treatment of CVDs, which lays a foundation for further exploration of the role of EVs, and clarifies the prospect of EVs in the treatment of myocardial injury.
Psychosocial Care for People With Diabetic Neuropathy: Time for Action
Authors: Frans Pouwer, Kara Mizokami-Stout, Neil D. Reeves, Rodica Pop-Busui, Solomon Tesfaye, Andrew J.M. Boulton, Loretta Vileikyte
Journal: Diabetes Care (2023)

Psychological factors and psychosocial care for individuals with diabetic neuropathy (DN), a common and burdensome complication of diabetes, are important but overlooked areas. In this article we focus on common clinical manifestations of DN, unremitting neuropathic pain, postural instability, and foot complications, and their psychosocial impact, including depression, anxiety, poor sleep quality, and specific problems such as fear of falling and fear of amputation. We also summarize the evidence regarding the negative impact of psychological factors such as depression on DN, self-care tasks, and future health outcomes. The clinical problem of underdetection and undertreatment of psychological problems is described, together with the value of using brief assessments of these in clinical care. We conclude by discussing trial evidence regarding the effectiveness of current pharmacological and nonpharmacological approaches and also future directions for developing and testing new psychological treatments for DN and its clinical manifestations.
A blueprint for elimination of cervical cancer
Authors: None The Lancet Infectious Diseases
Journal: The Lancet Infectious Diseases (2023)

On Nov 17, countries around the world marked the third Cervical Cancer Elimination Day of Action with renewed commitments, mass screening, and awareness campaigns. The first Day of Action in 2020 saw 194 countries commit to the elimination of cervical cancer within the next century and the launch by WHO of its Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Cervical cancer is the first noncommunicable disease to be targeted for elimination, which is possible because most cases are caused by oncogenic subtypes of the human papillomavirus (HPV), for which highly effective screening strategies and vaccines are available.
Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study
Authors: Donavon Sandoval-Heglund, Eric Roberts, Joonsuk Park, Maria Dall'Era, Cristina Lanata, Kamil E Barbour, Kurt J Greenlund, Caroline Gordon, Patricia P Katz, Jinoos Yazdany
Journal: The Lancet Rheumatology (2023)

Social determinants of health are consistently associated with systemic lupus erythematosus (SLE) outcomes. However, social determinants of health are typically measured with conventional socioeconomic status factors such as income or education. We assessed the association of economic insecurities (ie, food, housing, health care, and financial insecurity) with patient-reported outcomes in a cohort of patients with SLE.
Dissecting the heterogeneity of “in the wild” stress from multimodal sensor data
Authors: Sujay Nagaraj, Sarah Goodday, Thomas Hartvigsen, Adrien Boch, Kopal Garg, Sindhu Gowda, Luca Foschini, Marzyeh Ghassemi, Stephen Friend, Anna Goldenberg
Journal: npj Digital Medicine (2023)

Abstract Stress is associated with numerous chronic health conditions, both mental and physical. However, the heterogeneity of these associations at the individual level is poorly understood. While data generated from individuals in their day-to-day lives “in the wild” may best represent the heterogeneity of stress, gathering these data and separating signals from noise is challenging. In this work, we report findings from a major data collection effort using Digital Health Technologies (DHTs) and frontline healthcare workers. We provide insights into stress “in the wild”, by using robust methods for its identification from multimodal data and quantifying its heterogeneity. Here we analyze data from the Stress and Recovery in Frontline COVID-19 Workers study following 365 frontline healthcare workers for 4–6 months using wearable devices and smartphone app-based measures. Causal discovery is used to learn how the causal structure governing an individual’s self-reported symptoms and physiological features from DHTs differs between non-stress and potential stress states. Our methods uncover robust representations of potential stress states across a population of frontline healthcare workers. These representations reveal high levels of inter- and intra-individual heterogeneity in stress. We leverage multiple stress definitions that span different modalities (from subjective to physiological) to obtain a comprehensive view of stress, as these differing definitions rarely align in time. We show that these different stress definitions can be robustly represented as changes in the underlying causal structure on and off stress for individuals. This study is an important step toward better understanding potential underlying processes generating stress in individuals.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
Authors: Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John D Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie Crofford, Ronald F van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Tom WJ Huizinga, Ellen M Gravallese
Journal: Annals of the Rheumatic Diseases (2023)

The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology, immunology, infectious diseases, epidemiology, molecular biology and other specialties relating to all aspects of immune-mediated inflammatory diseases. We held breakout sessions in five rheumatological disease-specific groups including: rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpa), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and vasculitis, and osteoarthritis (OA). In each group, experts were asked to identify and prioritise current unmet needs in clinical and translational research. An overarching theme across all disease states is the continued need for clinical trial design innovation with regard to therapeutics, endpoint and disease endotypes. Within RA, unmet needs comprise molecular classification of disease pathogenesis and activity, pre-/early RA strategies, more refined pain profiling and innovative trials designs to deliver on precision medicine. Continued scientific questions within
Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease
Authors: Emma Tierney, Pamela Evans, Valerie Broderick, Robert Wynn, Alan D Irvine
Journal: British Journal of Dermatology (2023)

Therapeutic strategies with proven efficacy for chronic cutaneous graft-versus-host disease (GvHD) are limited, with long-term oral glucocorticoids remaining the first-line treatment. Prolonged treatment with glucocorticoids contributes to the significantly increased risk of nonrelapse mortality and substantial deficit in quality of life reported in paediatric transplant patients with chronic GvHD. We report a case of atopic dermatitis-like chronic cutaneous GvHD responding to dupilumab, allowing for the eventual withdrawal of oral glucocorticoids.
Long-Term Exposure to Low Concentrations of Ambient Benzene and Mortality in a National English Cohort
Authors: Jianing Wang, Yudiyang Ma, Linxi Tang, Dankang Li, Junqing Xie, Yu Sun, Yaohua Tian
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Benzene affects human health through environmental exposure in addition to occupational contact. However, few studies have examined the associations between long-term exposure to low concentrations of ambient benzene and mortality risks in nonoccupational settings.
Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial
Authors: Sophia Zoungas, Zhen Zhou, Alice J Owen, Andrea J Curtis, Sara E Espinoza, Michael E Ernst, Robyn L Woods, Suzanne G Orchard, John J McNeil, Anne M Murray, Mark R Nelson, Christopher M Reid, Joanne Ryan, Rory Wolfe
Journal: The Lancet Diabetes & Endocrinology (2023)
Methodological issues in the evaluation of cold snare endoscopic mucosal resection for colon polyps
Authors: Xiu-He Lv, Qing Lu, Jin-Lin Yang
Journal: Endoscopy (2023)

See also: Cold snare endoscopic mucosal resection for colon polyps: a systematic review and meta-analysisEndoscopy 2023; 55(12): 1083-1094DOI: 10.1055/a-2129-5752 See also: Cold snare endoscopic mucosal resection for colonic polyps: addressing methodological critiques and enhancing future discussionsEndoscopy 2024; 56(01): 79-80DOI: 10.1055/a-2162-7890
Deep learning for [18F]fluorodeoxyglucose-PET-CT classification in patients with lymphoma: a dual-centre retrospective analysis
Authors: Ida Häggström, Doris Leithner, Jennifer Alvén, Gabriele Campanella, Murad Abusamra, Honglei Zhang, Shalini Chhabra, Lucian Beer, Alexander Haug, Gilles Salles, Markus Raderer, Philipp B Staber, Anton Becker, Hedvig Hricak, Thomas J Fuchs, Heiko Schöder, Marius E Mayerhoefer
Journal: The Lancet Digital Health (2023)

The rising global cancer burden has led to an increasing demand for imaging tests such as [
Endoscopy E-Videos – recently published
Journal: Endoscopy (2023)

Comment on: Cholangioscopy in IgG4-related sclerosing cholangitis using texture and color enhancement imaging and red dichromatic imagingEndoscopy 2023; 55(S 01): E1019-E1020DOI: 10.1055/a-2155-4853 Comment on: Endoscopic closure of a rectovaginal fistula following surgery for endometriosis using the MARCEAU systemEndoscopy 2023; 55(S 01): E1023-E1024DOI: 10.1055/a-2155-3708 Comment on: Successful closure of thoracogastric airway fistula with occluder devices and coils under fluoroscopic guidanceEndoscopy 2023; 55(S 01): E1075-E1076DOI: 10.1055/a-2155-3369 Comment on: Endoscopic ultrasound-guided caudate lobe liver abscess drainageEndoscopy 2023; 55(S 01): E1099-E1100DOI: 10.1055/a-2174-5604
Endoscopy International Open – recently published
Journal: Endoscopy (2023)

Comment on: Optimal timing of simethicone administration prior to upper endoscopy: A multicenter, single-blind, randomized controlled trialEndosc Int Open 2023; 11(10): E992-E1000DOI: 10.1055/a-2157-5034 Comment on: Preferred techniques for endoscopic ultrasound-guided gastroenterostomy: a survey of expert endosonographersEndosc Int Open 2023; 11(11): E1035-E1045DOI: 10.1055/a-2185-6426 Comment on: Cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis: a prospective international cohort studyEndosc Int Open 2023; 11(11): E1056-E1062DOI: 10.1055/a-2165-7436
Commentary
Authors: Maren Haslach-Häfner, Klaus Mönkemüller
Journal: Endoscopy (2023)

Comment on: Endoscopic closure of a refractory urethroanal fistula using an innovative wound closure deviceEndoscopy 2023; 55(S 01): E1105-E1107DOI: 10.1055/a-2177-3695
Cold snare endoscopic mucosal resection for colonic polyps: addressing methodological critiques and enhancing future discussions
Authors: Mouhand F. H. Mohamed, Mohamed Abdallah, Khalid Ahmed, Fouad Jaber, Mohammad Bilal
Journal: Endoscopy (2023)

See also: Methodological issues in the evaluation of cold snare endoscopic mucosal resection for colon polypsEndoscopy 2024; 56(01): 79-79DOI: 10.1055/a-2162-8583
Comments on “Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared with sporadic lesions: a propensity score-matched cohort”
Authors: Jiankun Wang, Li Liu, Zhining Fan
Journal: Endoscopy (2023)

Letter to: Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared with sporadic lesions: a propensity score-matched cohortEndoscopy 2023; 55(08): 709-718DOI: 10.1055/a-2029-2935
Welcome to ESGE at 60 years
Authors: Mario Dinis-Ribeiro, Ian M. Gralnek
Journal: Endoscopy (2023)

As the saying goes, “time flies”. It is hard to believe that ESGE is celebrating its 60th birthday. Thus, each month in 2024, in the journal Endoscopy, the ESGE’s official publication organ, we will feature a special article as part of a series of activities for “ESGE – Celebrating 60 Years of Advancing Quality in GI Endoscopy! As an introduction to this series, we wish to provide both some historical background on the ESGE and an overview on the upcoming special articles that will detail the current pathways that ESGE is on to achieve its mission and goals as a major medical society. We hope you will enjoy these articles shining a light on ESGE’s past, present, and future.
No-touch endoscopic full-thickness resection technique matches the surgical concept as far as possible
Authors: Tao Chen, Shalitanati Ailijiang, Lingnan He, Jingjing Lian, Meidong Xu
Journal: Endoscopy (2023)

See also: Comments on “No-touch endoscopic full-thickness resection technique for gastric gastrointestinal stromal tumors”Endoscopy 2024; 56(01): 80-81DOI: 10.1055/a-2147-0456
Foreword Endoscopy – Issue 1
Authors: Peter D. Siersema
Journal: Endoscopy (2023)

First and foremost, I would like to thank all the Co-Editors for their continued hard work this year. In 2023, we were delighted to welcome Marianne Arvanitakis (Belgium) as a Co-Editor to our Editorial Team, as well as three new Junior Co-Editors, Michiel Bronswijk (Belgium), Ana Carbajo (Spain) and Tiago Cúrdia Gonçalves (Portugal).
Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study
Authors: Heechul Nam, Jaejun Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Hee Yeon Kim, Seok-Hwan Kim, Myeong Jun Song, Jung-Hyun Kwon, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Journal: Liver Cancer (2023)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Despite the emergence of atezolizumab and bevacizumab (A + B) as standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC), a comprehensive understanding of the clinical significance of immune-related adverse events (irAEs) remains limited. We aimed to assess the impact of irAEs on patients with HCC undergoing A + B treatment. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; This multicentre retrospective study included consecutive patients with HCC who were treated with the A + B regimen from September 2020 to December 2022. Patients were categorized into three groups based on the severity of irAEs, ranging from those without any experience of irAEs to those with severe irAEs. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; This study included 150 patients with HCC, with a mean age of 63.3 years. Among them, 93.3% of patients were classified as Barcelona Clinic Liver Cancer stage C, 52.0% had portal vein tumour thrombosis (PVTT), and 60.7% extrahepatic spread. Patients were classified as follows: group 1 (&lt;i&gt;n&lt;/i&gt; = 84) had no irAEs, group 2 (&lt;i&gt;n&lt;/i&gt; = 37) had mild irAEs (grade 1-2), and group 3 (&lt;i&gt;n&lt;/i&gt; = 29) had severe irAEs (grade ≥3). The median overall survival (OS), progression-free survival (PFS), and time-to-treatment discontinuation (TTD) were 13.6, 5.7, and 3.6 months, respectively. Group 2 demonstrated significantly superior OS compared to group 1 (9.5 months) and group 3 (5.6 months), with a median OS of 23.0 months (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001). Furthermore, group 2 demonstrated significantly better outcomes in terms of PFS and TTD compared to both group 1 and group 3 (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001 for both). Multivariate analysis identified mild irAEs (hazard ratio [HR], 0.353; &lt;i&gt;p&lt;/i&gt; = 0.010), ALBI grade 1 (HR, 0.389; &lt;i&gt;p&lt;/i&gt; = 0.006), Child-Pugh class A (HR, 0.338; &lt;i&gt;p&lt;/i&gt; = 0.002), and the absence of PVTT (HR, 0.556; &lt;i&gt;p&lt;/i&gt; = 0.043) as independent predictors of better OS. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; Our study highlights the significant impact of irAE severity on the outcomes of patients with HCC receiving A + B. Notably, the occurrence of mild irAEs was independently associated with favourable survival, suggesting their potential role as surrogate indicators of HCC prognosis.
Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease
Authors: Yongshuai Han, Chengjie Gao, Yunfeng Liu, Huan Zhang, Shihui Wang, Huizhi Zhao, Weili Bao, Xinhua Guo, Francesca Vinchi, Cheryl Lobo, Patricia Shi, Avital Mendelson, Larry Luchsinger, Hui Zhong, Karina Yazdanbakhsh, Xiuli An
Journal: Blood (2023)
Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study
Authors: Emily L. Graul, Clementine Nordon, Kirsty Rhodes, Jonathan Marshall, Shruti Menon, Constantinos Kallis, Anne E. Ioannides, Hannah R. Whittaker, Nicholas S. Peters, Jennifer K. Quint
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Rationale: Cardiovascular events after chronic obstructive pulmonary disease (COPD) exacerbations are recognized. Studies to date have been post hoc analyses of trials, did not differentiate exacerbation severity, included death in the cardiovascular outcome, or had insufficient power to explore individual outcomes temporally.Objectives: We explore temporal relationships between moderate and severe exacerbations and incident, nonfatal hospitalized cardiovascular events in a primary care–derived COPD cohort.Methods: We included people with COPD in England from 2014 to 2020, from the Clinical Practice Research Datalink Aurum primary care database. The index date was the date of first COPD exacerbation or, for those without exacerbations, date upon eligibility. We determined composite and individual cardiovascular events (acute coronary syndrome, arrhythmia, heart failure, ischemic stroke, and pulmonary hypertension) from linked hospital data. Adjusted Cox regression models were used to estimate average and time-stratified adjusted hazard ratios (aHRs).Measurements and Main Results: Among 213,466 patients, 146,448 (68.6%) had any exacerbation; 119,124 (55.8%) had moderate exacerbations, and 27,324 (12.8%) had severe exacerbations. A total of 40,773 cardiovascular events were recorded. There was an immediate period of cardiovascular relative rate after any exacerbation (1–14 d; aHR, 3.19 [95% confidence interval (CI), 2.71–3.76]), followed by progressively declining yet maintained effects, elevated after one year (aHR, 1.84 [95% CI, 1.78–1.91]). Hazard ratios were highest 1–14 days after severe exacerbations (aHR, 14.5 [95% CI, 12.2–17.3]) but highest 14–30 days after moderate exacerbations (aHR, 1.94 [95% CI, 1.63–2.31]). Cardiovascular outcomes with the greatest two-week effects after a severe exacerbation were arrhythmia (aHR, 12.7 [95% CI, 10.3–15.7]) and heart failure (aHR, 8.31 [95% CI, 6.79–10.2]).Conclusions: Cardiovascular events after moderate COPD exacerbations occur slightly later than after severe exacerbations; heightened relative rates remain beyond one year irrespective of severity. The period immediately after an exacerbation presents a critical opportunity for clinical intervention and treatment optimization to prevent future cardiovascular events.
Association of Diabetic Ketoacidosis in Childhood New-Onset Type 1 Diabetes With Day of Presentation in Germany
Authors: Clemens Kamrath, Marina Sindichakis, Marie Auzanneau, Silke Schmid, Hugo Segerer, Valentina Lahn, Sven Golembowsky, Dorothee Roessner-Cold, Kristina Rauh, Ulf Manuwald, Reinhard W. Holl
Journal: Diabetes Care (2023)

OBJECTIVE Whether the day of the week on which the child presents affects timely diagnosis and risk of diabetic ketoacidosis (DKA) in children with new-onset type 1 diabetes (T1D) is not known. RESEARCH DESIGN AND METHODS We used data of 30,717 children with new-onset T1D during the last 10 years from the German Prospective Diabetes Registry. We determined the odds ratios of T1D diagnosis and DKA on a weekday, public holiday, and school vacation. RESULTS Compared with workdays, the odds ratios of being diagnosed with T1D were lower on weekends (0.39 [95% CI, 0.38–0.41]), public holidays (0.57 [0.53–0.63]), and school vacations (0.83 [0.80–0.85]). The odds of DKA diagnosis were also reduced on weekends (0.55 [0.52–0.59]), public holidays (0.73 [0.63–0.84]), and school vacations (0.85 [0.80–0.90]). Results did not change during the coronavirus 2019 pandemic. CONCLUSIONS New-onset T1D and DKA in children are more often diagnosed during weekdays than weekends and holidays.